Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;94(10):4644-4653.
doi: 10.1002/jmv.27940. Epub 2022 Jun 29.

Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials

Affiliations

Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials

Fangyuan Tian et al. J Med Virol. 2022 Oct.

Abstract

To systematically review and synthesize the safety and efficacy of coronavirus disease-2019 (COVID-19) vaccines in children and adolescents. PubMed, EMBASE, Web of Science, Cochrane Library databases, the International Clinical Trials Registry Platform (ICTRP), the Chinese Clinical Trials Registry (ChiCTR), and ClinicalTrials.gov website were searched to collect accessible randomized controlled trials (RCTs) about the safety and efficacy of human COVID-19 vaccines in children and adolescents until May 1, 2022. Three steps, including duplicate removal, title and abstract screening, and full-text review, were used to screen the studies. The Cochrane risk-of-bias tool for RCTs was used to assess the bias risk of the included studies. Microsoft Excel 16.57 (2021) software was used for data extraction and analysis. (PROSPERO Code No: CRD42021295422). COVID-19 vaccines were evaluated in a total of 10 950 children and adolescents in seven published studies and over 49 530 participants in 26 ongoing randomized controlled trials. Descriptive findings of the included published studies were reported stratified by vaccine type. The overall, local, and systemic adverse events following immunization (AEFIs) reported in most trials were similar between the vaccine and placebo groups. Most of the reactions reported were mild to moderate, whereas a few were severe. The common adverse events were injection-site pain, fever, headache, cough, fatigue, and muscle pain. Few clinical trials reported serious adverse events, but most of them were unrelated to vaccination. In terms of efficacy, the investigated messenger RNA (mRNA) vaccine was found to be 90.7%-100% efficacious in preventing COVID-19 among children and adolescents, revealing good efficacy profiles in this age group. Among children and adolescents, the safety of current COVID-19 vaccines is acceptable, and studies have suggested that mRNA vaccines can provide high protection against COVID-19 infection in pediatric age groups.

Keywords: COVID-19 vaccines; children and adolescents; efficacy; safety; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diagram of the literature selection.

References

    1. WHO . Coronavirus disease COVID‐19. WHO coronavirus disease (COVID‐19) dashboard. Accessed February 7, 2022. https://covid19.who.int/
    1. Government of Canada . Coronavirus disease 2019 (COVID‐19): epidemiology update. Accessed March 6, 2022. https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid...
    1. European Centre for Disease Prevention and Control . COVID‐19. Accessed March 6, 2022. https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html
    1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology T . The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID‐19) ‐ China, 2020. China CDC Wkly. 2020;2:113‐122. - PMC - PubMed
    1. Government of Pakistan . Pakistan cases details. Accessed March 6, 2022. http://covid.gov.pk/stats/pakistan

Publication types

Substances